A scFv antibody fragment as a therapeutic candidate to neutralize a broad diversity of human IFN-alpha subtypes

Journal of Immunological Methods

Volumn 334, Issue 1-2, 2008, Pages 104-113

  Depetris, M ^a   Casalis, P ^a   Kratje, R ^a   Etcheverrigaray, M ^a   Oggero, M ^a  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Autoimmune diseases; Interferon alpha 2b; Neutralizing antibody; scFv

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; LEUKOCYTE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CLONING, MOLECULAR; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION;

MURINAE;

EID: 41949118164     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.02.003     Document Type: Article

References (25)

1. Bayer E.A., Skultesky E., and Wilchek M. The avidin-biotin complex in affinity cytochemistry. Methods Enzymol. 62 (1979) 308
2. Batteux F., Palmer P., Daeron M., Weill B., and Lebon P. FcgammaRII (CD32) dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur. Cytokine Netw. 10 4 (1999) 509
3. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., and Whitlow M. Single-chain antigen-binding proteins. Science 242 (1988) 423
4. Cadwell R.C., and Joyce G.F. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2 (1992) 28
5. Ceaglio N., Etcheverrigaray M., Kratje R., and Oggero M. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie 90 3 (2007) 437
6. Chothia C., and Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196 (1987) 901
7. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., and Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77 (1985) 305
8. Galfrè G., and Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 73 (1981) 3
9. Gill S.C., and von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182 (1989) 319
10. Gutterman I.U. Cytokine therapeutics: lesson from interferon α. Proc. Natl. Acad. Sci. U. S. A. 88 (1994) 1198
11. Huang X., Yuang J., Goddard A., Foulis A., James R.F., Lernmark A., Pujol-Borrell R., Rabinovitch A., Somoza N., and Stewart T.A. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44 (1995) 658
12. Kontsek P. Human type I interferons: structure and function. Acta Virol. 38 (1994) 345
13. Kramer A., Biggar R.J., Hampl H., Friedman R.M., Fuchs D., Wachter D., and Goedert J.J. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am. J. Epidemiol. 136 (1992) 71
14. Krebber A., Bornhauser S., Burmester J., Honegger A., Willuda J., Bosshard H.R., and Pluckthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods 201 (1997) 35
15. Kuroki M. A simple solid-phase competition assay with labeled antigen. In: Morris G.E. (Ed). Methods in Molecular Biology, vol. 66: Epitope Mapping Protocols (1996), Humana Press Inc., Totowa, New Jersey 47
16. Meager, A., 1998. Interferons alfa, beta and omega. In: Thorpe, R. (Ed.) Cytokines. Mire-Sluis, A.R. and Academic Press, London, p. 361.
17. Mogensen K.E., Lewerenz M., Reboul J., Lutfalla G., and Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J. Interferon Cytokine Res. 19 (1999) 1069
18. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., and Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202 (2005) 135
19. Noll F., Handschack W., Eichmannm E., Gaestel M., Schnedier F., Kuhl R., and Loster K. Production and characterization of four monoclonal antibodies specific for human interferon-alpha-1 and -alpha-2. Biomed. Biochim. Acta 48 (1989) 165
20. Roberts R.M., Liu L., Guo Q., Leaman D., and Bixby J. The evolution of the type I interferons. J. Interferon Cytokine Res. 18 (1998) 805
21. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd ed. (1990), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
22. Stevens F.J. Modification of an ELISA-based procedure for affinity determination: correction necessary for use with bivalent antibody. Mol. Immunol. 24 (1987) 1055
23. Viscomi G.C., Antonelli G., Buno C., Scapol L., Malavasi F., Funaro A., Simeón E., Pestka S., De Pisa F., and Dianzani F. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies. J. Interferon Cytokine Res. 19 (1999) 319
24. Waldmann T. Monoclonal antibodies in diagnosis and therapy. Science 252 (1991) 1657
25. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., and Rappaport J. Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3851